quadrivalent human papillomavirus vaccine

The HPV quadrivalent vaccine is a recombinant multivalent vaccine designed to prevent infections and associated diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18. It is composed of non-infectious virus-like particles (VLPs) assembled from the L1 major capsid protein of each targeted HPV genotype. HPV types 16 and 18 are high-risk genotypes responsible for approximately 70% of cervical cancer cases worldwide, as well as a significant proportion of anal, vulvar, and vaginal cancers. HPV types 6 and 11 are low-risk genotypes that cause the majority of genital warts (condyloma acuminata). The vaccine works by stimulating the immune system to produce neutralizing antibodies that prevent the virus from entering host cells. While the first approved quadrivalent vaccine, Gardasil (developed by Merck), is produced in *Saccharomyces cerevisiae*, other candidates, such as the one developed by Shanghai Bowei Biological and evaluated in Phase III trials by the Hunan Provincial CDC, utilize alternative expression systems like *Hansenula polymorpha*. These vaccines are typically formulated with an aluminum-based adjuvant and administered via intramuscular injection.

Brand names

Gardasil

Other names

HPV 4-valent vaccineHPV4-valent vaccineHPV-4-valent vaccine4vHPVRecombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) VaccineRecombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (Hansenulapolymorpha)